These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 19267353

  • 1. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R.
    Prostate; 2009 Jun 01; 69(8):895-907. PubMed ID: 19267353
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
    Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group.
    Contemp Clin Trials; 2007 Nov 01; 28(6):770-9. PubMed ID: 17761460
    [Abstract] [Full Text] [Related]

  • 3. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 01; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 4. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):389-402. PubMed ID: 18471794
    [Abstract] [Full Text] [Related]

  • 5. 5alpha-reductase inhibition for men with enlarged prostate.
    Issa MM, Kraft KH.
    J Am Acad Nurse Pract; 2007 Aug 01; 19(8):398-407. PubMed ID: 17655569
    [Abstract] [Full Text] [Related]

  • 6. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep 01; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 7. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group.
    J Urol; 2008 Feb 01; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [Abstract] [Full Text] [Related]

  • 8. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
    Issa MM, Runken MC, Grogg AL, Shah MB.
    Am J Manag Care; 2007 Feb 01; 13 Suppl 1():S10-6. PubMed ID: 17295600
    [Abstract] [Full Text] [Related]

  • 9. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb 01; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 10. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB, Parekh DJ.
    Curr Opin Urol; 2009 May 01; 19(3):238-42. PubMed ID: 19318950
    [Abstract] [Full Text] [Related]

  • 11. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J, Altwein J.
    Prostate Cancer Prostatic Dis; 2009 May 01; 12(2):130-6. PubMed ID: 19030020
    [Abstract] [Full Text] [Related]

  • 12. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 13. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Andriole GL.
    Urology; 2009 May 01; 73(5 Suppl):S36-43. PubMed ID: 19375625
    [Abstract] [Full Text] [Related]

  • 14. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 01; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological approaches to reducing the risk of prostate cancer.
    Rittmaster RS, Fleshner NE, Thompson IM.
    Eur Urol; 2009 May 01; 55(5):1064-73. PubMed ID: 19200641
    [Abstract] [Full Text] [Related]

  • 16. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec 01; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 17. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group.
    Contemp Clin Trials; 2007 Nov 01; 28(6):763-9. PubMed ID: 17573244
    [Abstract] [Full Text] [Related]

  • 18. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC, Davis EA, Shah MB, Lin PJ.
    Am J Manag Care; 2008 May 01; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [Abstract] [Full Text] [Related]

  • 19. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS.
    N Engl J Med; 1992 Oct 22; 327(17):1185-91. PubMed ID: 1383816
    [Abstract] [Full Text] [Related]

  • 20. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
    Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.
    J Urol; 2005 Dec 22; 174(6):2098-104. PubMed ID: 16280736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.